Company intelligence / Profile preview

Phidea

Bresso, Lombardy, Italy

Ownership: Private
Development stage: Other

Overview

Phidea is an Italian pharmaceutical company and a subsidiary of the Zambon Group, specializing in the respiratory and central nervous system (CNS) therapeutic areas. Founded in 1994 and acquired by Zambon in 2008, the company plays a key role in the commercialization and development of specialty medicines within the Italian market. Its portfolio is highlighted by treatments for Parkinson's disease, such as safinamide (Xadago), and various respiratory conditions. Phidea operates out of the OpenZone science park in Bresso, leveraging integrated R&D and manufacturing capabilities to address unmet medical needs in chronic and rare diseases.

Therapeutic areas: PulmonologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Newron Pharmaceuticals

Beyond the preview

Go deeper on Phidea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phidea.

Explore the full profile